| abstract |
Novel farnesyl derivatives which are inhibitors of the prenylated protein methyltransferase enzyme, and useful as anti-cancer drugs, have formula (I), wherein R1 represents farnesyl, geranyl or geranyl-geranyl; Z represents C-R2 or N; R2 represents H, CN, the groups COOR7, SO3R?7, CONR7R8¿ and SO¿2NR?7R7, wherein R?7 and R8¿ are each independently hydrogen, alkyl, alkenyl, and the groups COOM and SO¿3?M, wherein M is a cation; R?3, R4, R5 and R6¿ are each independently hydrogen, carboxyl, alkyl, alkenyl, aminoalkyl, nitroalkyl, nitro, halo, amino, mono- or di-alkylamino, mercapto, mercaptoalkyl, azido, or thiocyanato; X represents O, S, SO, SO¿2?, NH or Se; and the quaternary ammonium salts and N-oxides of the compounds of formula (I) wherein Z is N. |